Danish Pharmacovigilance Update, 16 February 2012

05 March 2012

In this issue of Danish Pharmacovigilance Update:

  • Risk of overdose with methotrexate in the treatment of rheumatoid arthritis and psoriasis (front page)
  • Gilenya (fingolimod) – intensified monitoring of heart rate and blood pressure after first dose (front page)
  • Newest data on the safety of methylphenidate (Ritalin etc.) in ADHD therapy (pp 2-3)
  • Risk of thromboembolism or death after discontinuation of anticoagulant therapy in patients with atrial fibrillation (pp 4-5)
  • Risk of venous thromboembolism from the use of 4th generation contraceptive pills (Yasmin® etc.) (p 6)
  • New report from the Danish Medicines Agency about the use of contraceptive pills and risk of thrombosis (pp 6-7)
  • Gilenya and macular oedema (p 7)
  • Haemorrhagic disease in a newborn whose mother was treated with valproate during pregnancy (p 8)
  • Study of the linkage between urine-derived fertility products and Creutzfeldt-Jakob (p 9)
  • The Danish Medicines Agency has drawn up a new report on pregnancy and adverse reactions from antidepressants (p 10)
  • New mobile app for checking medicines (p 10)